These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 37916308)

  • 1. Inhibitory effect of adenosine on adaptive antitumor immunity and intervention strategies.
    Wang L; Zhang W; Zhang J; Zheng M; Pan X; Guo H; Ding L
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Sep; 52(5):567-577. PubMed ID: 37916308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies.
    Wang L; Zhang J; Zhang W; Zheng M; Guo H; Pan X; Li W; Yang B; Ding L
    Acta Pharm Sin B; 2024 May; 14(5):1951-1964. PubMed ID: 38799637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule AZD4635 inhibitor of A
    Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
    Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
    Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
    Cekic C; Day YJ; Sag D; Linden J
    Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting innate immunity for cancer immunotherapy.
    Yi M; Li T; Niu M; Mei Q; Zhao B; Chu Q; Dai Z; Wu K
    Mol Cancer; 2023 Nov; 22(1):187. PubMed ID: 38008741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.
    Moynihan KD; Opel CF; Szeto GL; Tzeng A; Zhu EF; Engreitz JM; Williams RT; Rakhra K; Zhang MH; Rothschilds AM; Kumari S; Kelly RL; Kwan BH; Abraham W; Hu K; Mehta NK; Kauke MJ; Suh H; Cochran JR; Lauffenburger DA; Wittrup KD; Irvine DJ
    Nat Med; 2016 Dec; 22(12):1402-1410. PubMed ID: 27775706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
    Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G
    Front Immunol; 2019; 10():925. PubMed ID: 31244820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
    Ohue Y; Nishikawa H
    Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy.
    Liu Z; Liu X; Shen H; Xu X; Zhao X; Fu R
    Front Immunol; 2022; 13():978377. PubMed ID: 36159861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
    Bai Y; Zhang X; Zheng J; Liu Z; Yang Z; Zhang X
    J Exp Clin Cancer Res; 2022 Oct; 41(1):302. PubMed ID: 36229853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
    Piovesan D; Tan JBL; Becker A; Banuelos J; Narasappa N; DiRenzo D; Zhang K; Chen A; Ginn E; Udyavar AR; Yin F; Paprcka SL; Purandare B; Park TW; Kimura N; Kalisiak J; Young SW; Powers JP; Schindler U; Sivick KE; Walters MJ
    Mol Cancer Ther; 2022 Jun; 21(6):948-959. PubMed ID: 35405741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.
    Zhang PF; Wang C; Zhang L; Li Q
    Immunotherapy; 2022 Apr; 14(6):459-473. PubMed ID: 35232284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.